An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).
| Study Arm | Population | Intervention | Comparison | Outcome |
|---|---|---|---|---|
Previously untreated advanced squamous NSCLC |
Tislelizumab + Paclitaxel + Carboplatin |
Tislelizumab + Nab-paclitaxel + Carboplatin Paclitaxel + Carboplatin |
Primary Endpoint: PFS (IRC) Key Secondary Endpoints: ORR, DoR, OS, Safety |
